Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2010 Oct 15;25(13):2148-55.
doi: 10.1002/mds.23251.

Characteristics of the sequence effect in Parkinson's disease

Affiliations
Clinical Trial

Characteristics of the sequence effect in Parkinson's disease

Suk Yun Kang et al. Mov Disord. .

Abstract

The sequence effect (SE) in Parkinson's disease (PD) is progressive slowing of sequential movements. It is a feature of bradykinesia, but is separate from a general slowness without deterioration over time. It is commonly seen in PD, but its physiology is unclear. We measured general slowness and the SE separately with a computer-based, modified Purdue pegboard in 11 patients with advanced PD. We conducted a placebo-controlled, four-way crossover study to learn whether levodopa and repetitive transcranial magnetic stimulation (rTMS) could improve general slowness or the SE. We also examined the correlation between the SE and clinical fatigue. Levodopa alone and rTMS alone improved general slowness, but rTMS showed no additive effect on levodopa. Levodopa alone, rTMS alone, and their combination did not alleviate the SE. There was no correlation between the SE and fatigue. This study suggests that dopaminergic dysfunction and abnormal motor cortex excitability are not the relevant mechanisms for the SE. Additionally, the SE is not a component of clinical fatigue. Further work is needed to establish the physiology and clinical relevance of the SE. © 2010 Movement Disorder Society.

PubMed Disclaimer

Figures

FIG. 1
FIG. 1
An example of the order of the four interventions: levodopa and rTMS, levodopa and sham, placebo and rTMS, placebo and sham. The orders of the four interventions were randomly assigned.
FIG. 2
FIG. 2
Sequence effect (SE) in 11 patients pre-intervention over four interventions. Circles indicate time to move the first four pegs (1st–4th) (open circles) and time to move the last four pegs (5th–8th) (closed circles) (individual data as circles, group averages as bars). Increased mean value in closed circles indicates a SE (progressive slowing during peg movements) and decreased mean value indicates the opposite (speeding up during peg movements). The SE was significant in peg movements with the right hand, but did not reach a level of significance with the left hand (right hand, p=0.04; left hand, p=0.28; paired t-test).
FIG. 3
FIG. 3
(%) Relative change of general slowness in the right hand of PD patients. General slowness is defined as total time for eight peg movements. The y-axis shows the value (mean±SEM) of (%) relative change for the general slowness between pre- and post-intervention in 11 patients. A positive value indicates increased total time after intervention; a negative value indicates decreased total time after intervention. There was a significant improvement of (%) relative change in peg movements between rTMS and sham stimulation in the placebo condition (*p<0.05).
FIG. 4
FIG. 4
(%) Relative change of sequence effect (SE) in the right hand of PD patients. The y-axis shows (mean±SEM value of the (%) relative change in the SE between pre- and post-intervention in 11 patients. A positive value indicates that the intervention did not reverse the SE; A negative value indicates improvement of the SE after intervention. There was no significant difference among the four interventions (p>0.1).

Similar articles

Cited by

References

    1. Berardelli A, Rothwell JC, Thompson PD, Hallett M. Pathophysiology of bradykinesia in Parkinson’s disease. Brain. 2001;124:2131–2146. - PubMed
    1. Evarts EV, Teravainen H, Calne DB. Reaction time in Parkinson’s disease. Brain. 1981;104:167–186. - PubMed
    1. Berardelli A, Dick JP, Rothwell JC, Day BL, Marsden CD. Scaling of the size of the first agonist EMG burst during rapid wrist movements in patients with Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1986;49:1273–1279. - PMC - PubMed
    1. Velasco F, Velasco M. A quantitative evaluation of the effects of L-dopa on Parkinson’s disease. Neuropharmacology. 1973;12:89–99. - PubMed
    1. Jahanshahi M, Brown RG, Marsden CD. The effect of withdrawal of dopaminergic medication on simple and choice reaction time and the use of advance information in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1992;55:1168–1176. - PMC - PubMed

Publication types

MeSH terms